62%
Finnrick rating
#1 of 57 Semaglutide vendors
2 of 4 classifiable tests passed
natural 50% · customers 5.0★ (2)
methodology · Purity focus
Finnrick analysis · Semaglutide

Xian Yihang Technology's purity-focus evidence is strongest in BPC-157 and recent Tirzepatide rebounds, while Retatrutide and GHK-Cu expose the main weaknesses. Results are dispersed rather than uniform, with mixed recent purity, a GHK-Cu identity/fill outlier, and sparse batch IDs limiting traceability despite current, moderate-volume evidence.

methodology →
vendor intelligence report
Vendor Intelligence Report: Xian Yihang Technology

Platform records tie the eCHEMI supplier, Yihang Biochemical site, and TopXPeptide/YH Peptide retail brand through shared contacts, domains, and Xi'an addresses. The report also traces a missing first shop, unverified certification claims, and a catalog that reaches into regulated drug compounds.

25 pages5 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.07
82%
7
2
Tirzepatide
$0.24
79%
28
3
Retatrutide
$0.40
72%
22
4
BPC-157
-
64%
5
5
Semaglutideselected
$0.27
62%
4
6
Tesamorelin
$1.71
50%
7
7
TB-500
-
39%
4
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%4 Sept 2025: 70%3 Mar 2026: 73%3 Mar 2026: 68%13 Jul 2026: 62%25 Jul 2026: current 62%70%73%62%Sep 25Jul 26
Showing Semaglutide tests only
Xian Yihang Technology Semaglutide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
13 Jul 2026Fail
Tested
lab nameView COA
3 Mar 2026Fail
Tested
lab nameView COA
3 Mar 2026Pass
Tested
lab nameView COA
4 Sep 2025Pass
Tested
lab nameView COA

About Xian Yihang Technology test results from Finnrick

Xian Yihang Technology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 7 peptides and 77 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Xian Yihang Technology peptides in this dataset are Tirzepatide (28 tests), BPC-157 (5 tests) and Semaglutide (4 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 77 recent tests.

Corrections
No corrections.